表紙
市場調査レポート

ナノバイオテクノロジー:世界の市場とアプリケーション

Nanobiotechnology: Applications and Global Markets

発行 BCC Research 商品コード 140091
出版日 ページ情報 英文
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
ナノバイオテクノロジー:世界の市場とアプリケーション Nanobiotechnology: Applications and Global Markets
出版日: 2011年01月01日 ページ情報: 英文
概要

当レポートでは、世界のナノバイオテクノロジー市場の現状と見通しについて調査分析し、ナノバイオテクノロジーの概要・発展の経緯・バリューチェーン、プラットフォーム・アプリケーション・地域別の市場規模実績・予測(〜2015年)、特許状況、主要企業のプロファイルなどをまとめ、概略下記の内容でお届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • イントロダクション
  • ナノバイオテクノロジー市場の潜在性
  • ナノバイオテクノロジーの成長牽引因子
  • ナノバイオテクノロジー材料のプラットフォーム
  • ナノバイオテクノロジー製品の製品ライフサイクルの状況
  • ナノバイオテクノロジー産業

第4章 ナノバイオテクノロジー

  • ナノバイオテクノロジー
  • 歴史
  • バリューチェーン
  • バイオナノ材料
    • 概要
    • アプリケーションの状況
    • ライフサイクルの状況
  • ナノ粒子
  • 量子ドット
  • リポゾーム
  • デンドリマー
  • ナノポア
  • ナノ結晶
  • ポリマー構造
  • 集積ナノ構造

第5章 ナノバイオテクノロジーのアプリケーション

  • イントロダクション
  • ドラッグデリバリー
    • 標的デリバリー
    • siRNAドラッグデリバリー
  • バイオロジックイメージング
  • シーケンシング
  • リサーチツール
  • 殺菌剤

第6章 産業構造

  • 産業概要
  • ドラッグデリバリー産業
  • ナノポアシーケンシング産業
  • 量子ドット産業
  • 買収・戦略的提携

第7章 ナノバイオテクノロジー市場

  • 市場成長牽引因子
  • ナノバイオテクノロジー市場:サマリー
    • ナノ製品 市場:プラットフォーム別
    • ナノ製品 市場:アプリケーション別
  • DNAシーケンシング市場
  • 診断市場
    • 診断市場:サマリー
    • MRI市場
    • インビトロ診断市場
    • インビトロ診断ナノ粒子市場
  • 殺菌剤市場
  • ドラッグデリバリー市場
  • ナノバイオテクノロジー市場:地域別

第8章 ナノバイオテクノロジー特許状況

  • ナノバイオテクノロジー特許:地域別
  • ドラッグデリバリー特許

第9章 企業プロファイル

目次
Product Code: NAN050A

Abstract

HIGHLIGHTS

  • The total market for nanobiotechnology products is $19.3 billion in 2010 and is growing at a compound annual growth rate (CAGR) of 9% to reach a forecast market size of $29.7 billion by 2015.
  • Medical applications, including drug delivery and microbicides, dominate today' s market, with sales of $19.1 billion in 2010. This market segment is growing at a compound annual growth rate (CAGR) of 8.7%, and is forecast to reach sales of $29 billion by 2015.
  • In the R&D tools market, DNA sequencing is an emerging growth opportunity for nanotechnologies. This sector is valued at $63 million in 2010 and is expected to increase at a 37% compound annual growth rate (CAGR) to reach $305 million in 2015.

STUDY GOALS AND OBJECTIVES

BCC' s goal for this study is to examine the status of current and emerging nanobiotechnologies and products and assess their worldwide growth potential over a 5-year period from 2010 to 2015. We are particularly interested in characterizing the nanobiotechnology market for drug delivery, diagnostics, R&D tools, microbicides, and DNA sequencing applications. A main focus of this report is drug delivery, where the majority of nanotechnology sales occur.

Our main objective is to present a comprehensive analysis of what constitutes the state-of-the-art for nanotech-enabled life science products and what the current and future commercial potential is for each of the key market segments.

REASONS FOR DOING THE STUDY

Nanotechnology is coming of age as a materials platform in multiple industries including the biotechnology industry. The unique properties that nanomaterials provide enable value-added performance in a range of life science applications, from encapsulating and releasing drugs to biologic imaging. At the same time, the drug industry is searching for ways to extend drugs coming off patent as well as to improve drug pharmacokinetics. The diagnostics industry is seeking ways to better image molecular events to meet demand for new medicines. Nanobiotechnology, representing a diverse range of applications and materials, is the result of these converging forces.

Several nanotechnology platforms are already established and providing significant revenues in drug delivery applications, as well as diagnostics, microbicides, and R&D tools. Significant nanotechnology drug formats include polymer, liposomal, and nanocrystal drugs. Diagnostic and microbicide formats include nanoparticles, quantum dots, and dendrimers. Nanopore formats are emerging in third-generation DNA sequencing applications.

Given the emerging nature of this industry, it is timely to analyze the key trends, markets, and industry dynamics to provide a useful basis for decision-making.

SCOPE OF REPORT

The study scope includes the major nanotechnology formats that are likely to become commercialized within the next 5 years. Each technology format is analyzed to determine its market status, impact on future market segments, and forecasted growth from 2010 through 2015. Technology issues and market-driving forces are discussed.

Influencing factors, including drug delivery needs, biologic imaging trends, industry structure, and patent trends, are also discussed.

BCC examines nanobiotechnology companies and industry alliances, nanomaterial consumption by end-user industry, and market-driving forces. We profile 115 nanobiotechnology companies.

METHODOLOGY

BCC presents an analysis of each of the key market segments that will be commercially important during the next 5 years: research tools, drug delivery, diagnostics, next-generation DNA sequencing, and microbicides.

Based on our analysis, we evaluate the potential applications of nanomaterial platforms in each of the major market segments and forecast sales revenues for 2010 through 2015.

For research tools and drug discovery and development, the study presents a forecast from 2010 through 2015 for each of the important nanomaterials and applications. For drug delivery, we forecast the market by nanomaterial and by clinical indication. For diagnostics, the report forecasts from 2010 through 2015 the demand by application, modality, and nanomaterial. For microbicides, the report forecasts from 2010 through 2015 the demand by application and nanomaterial. For DNA sequencing, the study forecasts market size by use and by sequencing generation. Finally, we forecast the overall nanobiotechnology market by geographical region.

INFORMATION SOURCES

BCC surveyed life science companies and research institutions to obtain data for this study. Included were research tool firms, diagnostics firms, drug firms, nanomaterials firms, and leading nanotechnology research institutions. In addition, we compiled data from secondary sources including industry, trade, and government

Table of Contents

CHAPTER ONE: INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF REPORT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER

CHAPTER TWO: SUMMARY

  • SUMMARY
  • SUMMARY TABLE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, THROUGH 2015 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY END USER, 2009- 2015 ($ MILLIONS)
  • SUMMARY (CONTINUED)

CHAPTER THREE: OVERVIEW

  • INTRODUCTION
    • TABLE 1. SCOPE OF THIS REPORT
  • MARKET POTENTIAL OF NANOBIOTECHNOLOGY
    • TABLE 2. GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
  • NANOBIOTECHNOLOGY GROWTH DRIVING FORCES
    • TABLE 3. NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES
  • NANOBIOTECHNOLOGY MATERIALS PLATFORMS
    • TABLE 4. GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS)
  • NANOBIOTECHNOLOGY PRODUCT LIFE CYCLE STATUS
    • TABLE 5. LIFE CYCLE STATUS OF NANOMATERIALS
  • NANOBIOTECHNOLOGY INDUSTRY
    • TABLE 6. NANOBIOTECHNOLOGY INDUSTRY
  • NANOBIOTECHNOLOGY INDUSTRY (CONTINUED)

CHAPTER FOUR: NANOBIOTECHNOLOGIES

  • NANOBIOTECHNOLOGY
    • TABLE 7. FEATURES OF NANOTECHNOLOGIES
  • HISTORY OF NANOTECHNOLOGY
    • TABLE 8. HISTORICAL TIMELINE OF NANOTECHNOLOGY, 1931-2007
  • NANOTECHNOLOGY VALUE CHAIN
    • TABLE 9. VALUE CHAIN FOR NANOTECHNOLOGIES
  • BIO-NANOMATERIALS
  • OVERVIEW
    • TABLE 10. NANOBIOTECHNOLOGY MATERIALS
  • APPLICATIONS STATUS
    • TABLE 11. NANOMATERIALS APPLICATIONS STATUS
  • LIFE CYCLE STATUS
    • TABLE 12. NANOMATERIALS LIFE CYCLE STATUS
  • NANOPARTICLES
  • NANOPARTICLES (CONTINUED)
    • TABLE 13. NANOPARTICLES IN IMAGING APPLICATIONS
  • QUANTUM DOTS
    • TABLE 14. COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT PROTEINS
    • FIGURE 1. QUANTUM DOT SPECTRA
    • FIGURE 2. FLUORESCENT DYE SPECTRA
  • LIPOSOMES
    • TABLE 15. LIPOSOME TYPES
  • DENDRIMERS
  • NANOPORES
  • TECHNICAL FEASIBILITY OF NANOPORE SEQUENCING NANOCRYSTALS
    • TABLE 16. ADVANTAGES OF NANOCRYSTAL DRUG TECHNOLOGY POLYMER STRUCTURES
  • INTEGRATED NANOSTRUCTURES
  • INTEGRATED NANOSTRUCTURES (CONTINUED)
  • INTEGRATED NANOSTRUCTURES (CONTINUED)

CHAPTER FIVE: NANOBIOTECHNOLOGY APPLICATIONS

  • INTRODUCTION
    • TABLE 17. NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX
  • DRUG DELIVERY APPLICATIONS
    • TABLE 18. BENEFITS OF IMPROVED DRUG DELIVERY
    • TABLE 19. KEY NANOMATERIALS IN DRUG DELIVERY
    • TABLE 20. NUMBER OF COMMERCIAL DRUGS USING NANOTECHNOLOGY, BY INDICATION, SEPTEMBER 2010
    • TABLE 21. MARKETED NANO-BASED DRUGS, 2010
    • TABLE 21. (CONTINUED)
    • TABLE 22. STATUS OF AMPHOTERICIN B
  • TARGETED DELIVERY
    • TABLE 23. TARGETED VERSUS NONTARGETED DRUG DELIVERY SIRNA DRUG DELIVERY
    • FIGURE 3. RNAI SYSTEMIC DELIVERY APPROACHES
  • BIOLOGIC IMAGING APPLICATIONS
    • TABLE 24. KEY BIOLOGIC IMAGING NANO-REAGENT TYPES
  • WHY NANOPARTICLES ARE IMPORTANT FOR IMAGING
  • SUMMARY OF NANOPARTICLE IMAGING APPLICATIONS
    • TABLE 25. NANOPARTICLES IN IMAGING APPLICATIONS
  • In Vivo Imaging
    • TABLE 26. NANOPARTICLE IN VIVO DIAGNOSTICS PIPELINE
    • TABLE 26. (CONTINUED)
  • In Vitro Imaging
    • TABLE 27. NANOSPHERE IN VITRO DIAGNOSTICS REAGENTS PIPELINE
  • Genomics, Proteomics and Cell Biology Imaging
  • EMERGING APPLICATIONS OF IMAGING REAGENTS
    • FIGURE 4. THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY
  • ADVANCED IMAGING NANO-REAGENTS
    • TABLE 28. EMERGING BIOLOGIC NANO-IMAGING REAGENT FUNCTIONS
  • Dual Modality Reagents
  • Multifunctional Reagents
  • Multiplexed Reagents
  • SEQUENCING APPLICATIONS
    • TABLE 29. SEQUENCING KEY NANOMATERIALS
    • TABLE 30. USE OF NANOMATERIALS, BY SEQUENCING PLATFORM
  • SEQUENCING APPLICATIONS (CONTINUED)
    • FIGURE 5. $1,000 GENOME PROGRAM AWARDS, BY TECHNOLOGY, 2007-2009
  • RESEARCH TOOLS APPLICATIONS
  • MICROBICIDE APPLICATIONS
    • TABLE 31. APPLICATIONS OF NANOMATERIALS IN MICROBICIDES

CHAPTER SIX: NANOBIOTECHNOLOGY INDUSTRY STRUCTURE

  • INDUSTRY OVERVIEW
    • TABLE 32. NANOBIOTECHNOLOGY MATERIALS/APPLICATIONS MATRIX
  • DRUG DELIVERY INDUSTRY
    • TABLE 33. DRUG DELIVERY INDUSTRY POSITION, BY NANOMATERIAL
    • TABLE 34. DRUG DELIVERY COMPETITOR POSITION
    • TABLE 34. (CONTINUED)
    • TABLE 34. (CONTINUED)
    • TABLE 34. (CONTINUED)
    • TABLE 35. COMPANIES SPECIALIZING IN DRUG DELIVERY OF BIOMOLECULES
  • NANOPORE SEQUENCING INDUSTRY
    • TABLE 36. SEQUENCING INSTRUMENT COMPETITORS, BY TECHNOLOGY
    • TABLE 36. (CONTINUED)
  • QUANTUM DOTS INDUSTRY
    • TABLE 37. QUANTUM DOTS KEY COMPETITORS
  • ACQUISITIONS AND STRATEGIC ALLIANCES
    • TABLE 38. NANOBIOTECHNOLOGY INDUSTRY ACQUISITIONS, 2007-2010
    • TABLE 39. NANOBIOTECHNOLOGY INDUSTRY STRATEGIC ALLIANCES, 2007-2010
    • TABLE 39. (CONTINUED)
  • ACQUISITIONS AND STRATEGIC ... (CONTINUED)
  • ACQUISITIONS AND STRATEGIC ... (CONTINUED)

CHAPTER SEVEN: NANOBIOTECHNOLOGY MARKETS

  • MARKET GROWTH DRIVING FORCES
    • TABLE 40. NANOBIOTECHNOLOGY MARKET GROWTH DRIVING FORCES
    • TABLE 41. NANOBIOTECHNOLOGY PEER-REVIEWED PUBLICATIONS, 1990-2009
  • NANOBIOTECHNOLOGY MARKET SUMMARY
  • NANOPRODUCTS MARKETS BY PLATFORM
    • TABLE 42. GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS)
  • NANOPRODUCTS MARKETS BY APPLICATION
    • TABLE 43. GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
    • TABLE 44. GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
    • TABLE 45. GLOBAL VALUE OF RESEARCH TOOLS MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS)
  • DNA SEQUENCING MARKET
    • TABLE 46. GLOBAL VALUE OF NANOBIOTECHNOLOGY SEQUENCING MARKET, THROUGH 2015 ($ MILLIONS)
    • TABLE 47. GLOBAL VALUE OF SANGER AND NEXT-GENERATION NANO-ENABLED SAMPLE PREPARATION MARKET, BY SEQUENCING GENERATION, THROUGH 2015 ($ MILLIONS)
    • TABLE 48. GLOBAL VALUE OF THE NANO-ENABLED NANOPORE SEQUENCING MARKET, BY PRODUCT TYPE, THROUGH 2015 ($ MILLIONS)
    • TABLE 49. GLOBAL VALUE OF THE NANO-ENABLED SEQUENCING MARKET, BY NANOPLATFORM, THROUGH 2015 ($ MILLIONS)
  • DIAGNOSTICS MARKET
  • DIAGNOSTICS MARKET SUMMARY
    • TABLE 50. GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
    • TABLE 51. GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY MODALITY, THROUGH 2015 ($ MILLIONS)
  • Diagnostics Market Summary (Continued)
    • TABLE 52. GLOBAL VALUE OF THE NANO-ENABLED DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS)
  • MRI MARKET
    • TABLE 53. GLOBAL VALUE OF THE NANO-ENABLED MRI DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS)
  • IN VITRO DIAGNOSTICS MARKETS
    • TABLE 54. GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY ASSAY TYPE, THROUGH 2015 ($ MILLIONS)
    • TABLE 55. GLOBAL VALUE OF THE NANO-ENABLED IN VITRO DIAGNOSTICS MARKET, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS)
  • IN VITRO DIAGNOSTICS NANOPARTICLES MARKETS
    • TABLE 56. GLOBAL VALUE OF NANOPARTICLE IN VITRO DIAGNOSTICS, BY NANO-PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 57. GLOBAL VALUE OF GOLD NANOPARTICLE IN VITRO DIAGNOSTICS, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
  • MICROBICIDES MARKET
    • TABLE 58. GLOBAL VALUE OF THE NANO-ENABLED MICROBICIDES MARKET, BY APPLICATION, THROUGH 2015 ($ MILLIONS)
    • FIGURE 6. BRANDED CONDOM MANUFACTURER WORLDWIDE MARKET SHARES, 2010 (%)
    • FIGURE 6. (CONTINUED)
    • TABLE 59. GLOBAL VALUE OF NANO-ENABLED MICROBICIDES MARKET, BY PLATFORM, THROUGH 2015 ($ MILLIONS)
  • DRUG DELIVERY MARKET
    • TABLE 60. GLOBAL VALUE OF DRUG DELIVERY NANOPRODUCTS MARKET, BY INDICATION, THROUGH 2015 ($ MILLIONS)
    • TABLE 61. GLOBAL VALUE OF THE NANO-ENABLED DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 62. GLOBAL VALUE OF THE NANO-ENABLED CANCER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 63. GLOBAL VALUE OF NANO-ENABLED CNS DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 64. GLOBAL VALUE OF NANO-ENABLED ANTI-INFECTIVE DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 65. GLOBAL VALUE OF NANO-ENABLED LIPID DISORDER DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
    • TABLE 66. GLOBAL VALUE OF NANO-ENABLED “OTHER” DRUG DELIVERY MARKET, BY TECHNOLOGY PLATFORM, THROUGH 2015 ($ MILLIONS)
  • NANOBIOTECHNOLOGY MARKETS BY GEOGRAPHY
    • TABLE 67. GLOBAL VALUE OF NANOBIOTECHNOLOGY MARKET, BY GEOGRAPHY, THROUGH 2015 ($ MILLIONS)

CHAPTER EIGHT: NANOBIOTECHNOLOGY PATENT STATUS

  • NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY
    • FIGURE 7. NUMBER OF NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010
    • FIGURE 7. (CONTINUED)
  • DRUG DELIVERY PATENTS
    • FIGURE 8. NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY NANOMATERIAL PLATFORM, 2000 TO SEPTEMBER 2010
    • FIGURE 9. NUMBER OF DRUG DELIVERY NANOBIOTECHNOLOGY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010 (%)
    • FIGURE 10. NUMBER OF LIPOSOMAL DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO 2010
    • FIGURE 10. (CONTINUED)
    • FIGURE 11. NUMBER OF NANOPARTICLE DRUG DELIVERY PATENTS BY GEOGRAPHY, 2000 TO SEPTEMBER 2010
    • FIGURE 11. (CONTINUED)

CHAPTER NINE: COMPANY PROFILES

  • ABBOTT GMBH & CO. KG
  • ABRAXIS BIOSCIENCE
  • ACCESS PHARMACEUTICALS, INC.
  • ACUSPHERE, INC.
    • TABLE 68. ACUSPHERE PRODUCT PIPELINE
    • TABLE 69. ACUSPHERE PATENT ESTATE
  • ACRYMED, INC.
  • AION DIAGNOSTICS
  • ALNIS BIOSCIENCES INC.
  • AMAG PHARMACEUTICALS, INC.
    • TABLE 70. AMAG MOLECULAR IMAGING REAGENTS PIPELINE
    • TABLE 71. AMAG MRI IMAGING REAGENTS MARKETING ALLIANCES
  • AGILENT TECHNOLOGIES, INC.
  • AGILENT TECHNOLOGIES, INC.(CONTINUED)
  • ALLERGAN, INC.
  • ALLTRACEL PHARMACEUTICALS, PLC
  • ALPHA RX, INC.
  • ANSON NANO-BIOTECHNOLOGY CO. LTD.
  • APHIOS CORPORATION
  • AQUANOVA AG
  • ARMAGEN TECHNOLOGIES, INC.
  • ARTIFICIAL CELL TECHNOLOGIES, INC.
  • AZAYA THERAPEUTICS
  • BASE4 INNOVATION LTD.
  • BAXTER INTERNATIONAL INC.
  • BBI INTERNATIONAL
  • BILCARE LIMITED
  • BIND BIOSCIENCES, INC.
  • BIOALLIANCE PHARMA
  • BIOCON
  • BIODELIVERY SCIENCES INTERNATIONAL, INC.
  • BIO-GATE AG
  • BIONANOMATRIX, INC.
  • BIOPHAN TECHNOLOGIES, INC.
  • BIOSANTE PHARMACEUTICALS INC.
  • BIO-SYNECTICS, INC.
  • CALANDO PHARMACEUTICAL
  • CAMURUS AB
  • CAPSULUTION PHARMA AG
  • CELSION CORPORATION
    • TABLE 72. CELSION LIPOSOMAL PLATFORM STATUS
  • CENTOCOR ORTHO BIOTECH INC.
  • CERAMISPHERE PTY LTD
  • CERULEAN PHARMA INC.
  • CHEMICELL GMBH
  • CRITITECH, INC.
  • CSL BEHRING
  • CYTIMMUNE SCIENCES, INC.
  • DAMAGE PREVENTION CONCEPT
  • DENDRITECH, INC.
  • ELAN CORPORATION PLC
  • ELECTRONIC BIO SCIENCES
  • ENDOCYTE
  • ENZON PHARMACEUTICALS
  • EPITARGET AS
  • EVIDENT TECHNOLOGIES
  • EXILICA LIMITED
  • FERROPHARM GMBH
  • FLAMEL TECHNOLOGIES
  • FRESNIUS KABI AG
  • GE HEALTHCARE UK LTD.
  • GILEAD SCIENCES, INC.
  • GRACEWAY PHARMACEUTICALS, LLC
  • HANA BIOSCIENCES, INC.
  • HUMAN GENOME SCIENCES
  • IMMUNOVACCINE
  • INDIANA NANOTECH LLC
  • INTERNATIONAL BUSINESS MACHINES CORP.
  • JOHNSON & JOHNSON, INC.
  • KEREOS, INC.
    • TABLE 73. KEREOS IMAGING REAGENTS PIPELINE
    • TABLE 74. KEREOS STRATEGIC ALLIANCES
  • LABOPHARM INC.
  • LIFECARE INNOVATIONS PVT. LTD.
  • LIPLASOME PHARMA APS
  • LIPOXEN
  • LUNA NANOWORKS
  • MARINA BIOTECH
  • MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD.
  • MYMETICS S.A.
  • NABSYS, INC.
  • NANOBIO CHEMICALS INDIA PRIVATE LIMITED
  • NANOBIOTIX
  • NANOBIOSYM, INC.
  • NANOCARRIER CO., LTD.
  • NANOCO TECHNOLOGIES LTD.
  • NANOCOPOEIA, INC.
  • NANOCYTE INC.
  • NANOPROBES, INC.
  • NANOSPECTRA BIOSCIENCES, INC.
  • NANOSPHERE, INC.
  • NANOTOX
  • NANOVECTOR, INC.
  • NATCO PHARMA LIMITED
  • NOVAVAX, INC.
  • NOVOSOM AG
  • NOVOZYMES BIOPHARMA US INC.
  • OCTOPLUS N.V.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • OXFORD NANOPORE TECHNOLOGIES LTD. (CONTINUED)
  • OXONICA INC.
  • PACIRA PHARMACEUTICALS
  • PANACEA BIOTEC LTD.
  • PCI BIOTECH AS
  • SALVONA TECHNOLOGIES INC.
  • SCHERING-PLOUGH
  • SELAH TECHNOLOGIES, LLC
  • SELECTA BIOSCIENCES
  • SEQUENOM, INC.
  • SEQUENOM, INC. (CONTINUED)
  • SEQUENOM, INC. (CONTINUED)
  • SEQUENOM, INC. (CONTINUED)
  • SIEMENS AG
  • SIGMA-TAU PHARMACEUTICALS, INC.
  • SKYEPHARMA PLC
  • SMITH & NEPHEW PLC
  • SNOGG AS
  • SOPHERION THERAPEUTICS, LLC
  • STARPHARMA HOLDINGS LTD
    • TABLE 75. STARPHARMA STRATEGIC ALLIANCES
  • SUPRATEK PHARMA
  • TEKMIRA PHARMACEUTICALS
  • TEVA PHARMACEUTICALS
  • UNIDYM, INC
  • VIVE NANO INC.
Back to Top